CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition

About this update from Cannabis Bioscience International Holdings, Inc.

[{"type":"text","content":"Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process.","length":435,"tagName":"p"},{"type":"text","content":"On December 18, 2025, a Presidential Executive Order directed the U.S. Attorney General to take necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III as expeditiously as permitted by law, while expanding pathways for medical marijuana and cannabidiol research. CBIH views this moment as an urgent implementation window-where science, patents, and credible education must move in parallel to ensure the policy direction translates into measurable outcomes.","length":502,"tagName":"p"},{"type":"text","content":"Since this federal directive, CBIH has intensified outreach-through calls, emails, and formal correspondence-to pharmaceutical companies, members of Congress, U.S. Senators, and federal stakeholders whose agencies and committees influence research pathways and execution, including (among others) the U.S. Department of Justice, the Drug Enforcement Administration (DEA), and the Centers for Medicare & Medicaid Services (CMS). CBIH's objective is to build working relationships that can help align clinical research standards, clarify available research mechanisms, and accelerate compliant programs supported by defensible intellectual property.","length":655,"tagName":"p"},{"type":"text","content":""Policy momentum alone is not enough," said Rosangel Andrades, MD, CBIH R&D Director. "The Schedule III transition is a once-in-a-generation inflection point-yet the real impact will be determined by execution: standards, research infrastructure, and the ability to translate science into compliant clinical pathways. We believe CBIH can help accelerate that execution."","length":394,"tagName":"p"},{"type":"text","content":"CBIH's platform includes investigational medical formulations targeting high-need conditions, a robust IP strategy, and a scalable education model designed ...

More updates from Cannabis Bioscience International Holdings, Inc.